2024
Metabotropic Glutamate Receptor 5 as a Potential Biomarker of the Intersection of Trauma and Cannabis Use
Weiss E, Davis M, Asch R, D'Souza D, Cool R, Esterlis I. Metabotropic Glutamate Receptor 5 as a Potential Biomarker of the Intersection of Trauma and Cannabis Use. The International Journal Of Neuropsychopharmacology 2024, 27: pyae044. PMID: 39320043, DOI: 10.1093/ijnp/pyae044.Peer-Reviewed Original ResearchTrauma-related psychopathologyCannabis useDepressive symptomsPositron emission tomographyCross-diagnostic sampleMetabotropic glutamate receptor 5Treatment development effortsAssociated with depressive symptomsGlutamate receptor 5CU groupSample of individualsAvailability in vivoFrontolimbic regionsGlutamatergic systemGlutamatergic neurotransmissionMGlu5PsychopathologyReceptor 5Intersection of traumaExploratory analysisCannabisEmission tomographySymptomsParticipantsVmPFCW35 Nicotine Use and Metabotropic Glutamate Receptor 5 (mGluR5) in Individuals With Major Depressive and Post Traumatic Stress Disorders
Baldassarri S, Asch R, Hillmer A, Pietrzak R, DellaGioia N, Esterlis I, Davis M. W35 Nicotine Use and Metabotropic Glutamate Receptor 5 (mGluR5) in Individuals With Major Depressive and Post Traumatic Stress Disorders. Drug And Alcohol Dependence 2024, 260: 110653. DOI: 10.1016/j.drugalcdep.2023.110653.Peer-Reviewed Original ResearchPreliminary Study of White Matter Abnormalities and Associations With the Metabotropic Glutamate Receptor 5 to Distinguish Bipolar and Major Depressive Disorders
Fan S, Asch R, Davis M, DellaGioia N, Cool R, Blumberg H, Esterlis I. Preliminary Study of White Matter Abnormalities and Associations With the Metabotropic Glutamate Receptor 5 to Distinguish Bipolar and Major Depressive Disorders. Chronic Stress 2024, 8: 24705470231225320. PMID: 38250007, PMCID: PMC10798116, DOI: 10.1177/24705470231225320.Peer-Reviewed Original ResearchMetabotropic glutamate receptor 5Bipolar disorderGlutamate receptor 5UF FAUncinate fasciculusFractional anisotropyWhole-brain analysisMultimodal neuroimaging approachDifferentiation of BDDiffusion-weighted MRI scansFrontotemporal dysconnectivityFrontotemporal systemFunctional dysconnectivityDepressive disorderNeurobiological mechanismsMGluR5 levelsWhite matterWhite matter abnormalitiesNeuroimaging approachesWM integrityNeural mechanismsMDDWhole-brainWM abnormalitiesReceptor 5
2023
Examining mGlu5 Receptor Availability as a Predictor of Vulnerability to PTSD: An [18F]FPEB and PET Study in Male and Female Rats
Asch R, Fowles K, Pietrzak R, Taylor J, Esterlis I. Examining mGlu5 Receptor Availability as a Predictor of Vulnerability to PTSD: An [18F]FPEB and PET Study in Male and Female Rats. Chronic Stress 2023, 7: 24705470231215001. PMID: 38024327, PMCID: PMC10666551, DOI: 10.1177/24705470231215001.Peer-Reviewed Original ResearchPost-traumatic stress disorderReceptor availabilityFemale ratsPathophysiology of PTSDFootshock exposureMetabotropic glutamate receptor 5Recent preclinical findingsGlutamate receptor 5Positron emission tomographyPreclinical findingsClinical findingsFe ratsReceptor 5Lower baselineEmission tomographyGreater riskPET studiesRatsStress disorderDifferential involvementPassive copingSex differencesMalesPTSD susceptibilityBaseline
2022
The metabotropic glutamate receptor 5 as a biomarker for psychiatric disorders
Asch R, Hillmer A, Baldassarri S, Esterlis I. The metabotropic glutamate receptor 5 as a biomarker for psychiatric disorders. International Review Of Neurobiology 2022, 168: 265-310. PMID: 36868631, DOI: 10.1016/bs.irn.2022.10.007.Peer-Reviewed Original ResearchConceptsPsychiatric disordersMetabotropic glutamate receptor 5Positron emission tomography studyGlutamate receptor 5Utility of PETEmission tomography studiesPromising therapeutic targetStress-related disordersNumerous psychiatric disordersTreatment trialsGlutamate neurotransmissionGlutamate systemMGlu5 expressionSubtype 5Treatment responseMood disordersRole of mGlu5Receptor 5Therapeutic targetPsychiatric conditionsMGlu5Tomography studySubstance useTrauma disordersDisordersDifferences in Quantification of the Metabotropic Glutamate Receptor 5 Across Bipolar Disorder and Major Depressive Disorder
Holmes S, Asch R, Davis M, DellaGioia N, Pashankar N, Gallezot J, Nabulsi N, Matuskey D, Sanacora G, Carson R, Blumberg H, Esterlis I. Differences in Quantification of the Metabotropic Glutamate Receptor 5 Across Bipolar Disorder and Major Depressive Disorder. Biological Psychiatry 2022, 93: 1099-1107. PMID: 36764853, PMCID: PMC10164841, DOI: 10.1016/j.biopsych.2022.10.018.Peer-Reviewed Original ResearchConceptsMajor depressive disorderMetabotropic glutamate receptor 5Glutamate receptor 5MGluR5 availabilityBipolar disorderPositron emission tomographyHC groupDepressive disorderReceptor 5Emission tomographyHealthy control individualsPossible treatment targetsGlutamate transmissionBD depressionTreatment strategiesBD groupMGluR5Depressive symptomsNovel treatmentsCognitive alterationsTreatment targetsSynaptic plasticityControl individualsAccurate diagnosisSignificant negative correlation